GrowBLOX Announces Deployment of Commercial Units
May 26 2015 - 1:29PM
Growblox Sciences, Inc. (OTCQB:GBLX), a biopharmaceutical company
with state-of-the-art technologies in plant biology and cultivation
designed to produce consistent medicinal cannabis, announced today
the receipt of production-model GrowBLOX™ units for both GB
Sciences Nevada (GBSN) and GB Sciences Puerto Rico (GBS PR).
"This is a major milestone for our company as it signals the
transition from development to commercialization of our unique
cannabis cultivation technology. We didn't set out to reinvent
cannabis cultivation, but we believe that 'if you can't measure it,
you can't control it'. Therefore, we had to invent a series of
proprietary chambers to control and monitor all stages of plant
growth from tissue culture in the TissueBLOX, to maturation in the
GrowBLOX, through curing in the CureBLOX," stated Craig Ellins, CEO
of Growblox Sciences, Inc. "All of the hardware and software
improvements that we discovered during the development phases have
been incorporated into these productions models, and we are eager
to begin the validation process driven largely from our Puerto Rico
location under the direction of Jorge Velez, Project Manager at GBS
PR. Jorge is a 25-year veteran of the pharmaceutical industry and
is ideally qualified to validate our technology according to
rigorous pharmaceutical standards."
Validation of the GrowBLOX™ technology suite will include the
development of a remote monitoring and diagnostic services program,
as well as tissue-culture propagation and plant-genotype, cryogenic
banking services. In addition, GBS PR will be responsible for
implementing the GBLX quality management system to assure that all
aspects of the cultivation of medical cannabis in the GrowBLOX™
technology suite conform to Current Good Manufacturing Practices
(or cGMP). As regulated by the FDA, cGMP processes are
followed by pharmaceutical and biotechnology firms to ensure that
their certified products meet specific requirements for identity,
strength, quality, and purity.
Dr. Andrea Small-Howard, Chief Science Officer of Growblox
Sciences noted, "Creating cGMP-certified cannabis materials is the
key to bringing cannabis and cannabis-based therapies out of
state-regulated dispensaries and into larger federally-regulated
markets including those for nutraceutical, cosmeceutical and
pharmaceutical products. These cGMP certified materials represent
the best starting point for scientifically validating the
effectiveness of cannabinoid therapies for patients within
regulated markets. Current studies of medical cannabis often lack
properly controlled and dosed starting materials, but our trials
will use standardized starting materials in order to evaluate the
effectiveness to FDA standards. Our diligence through the research
and development phase of our GrowBLOX technology suite was geared
toward meeting this pharmaceutical standard."
The GrowBLOX chambers had successfully completed several phases
of testing and re-design in order to maximize the efficiency of
this proprietary cultivation system. In May of 2014, GBLX had
reported that a development stage version of the GrowBLOX™ had been
produced for evaluation in China by Wayne Love, Lead Product
Engineer at GBLX. The first GrowBLOX™ units arrived in Las Vegas,
NV in August of 2014 for evaluation by Dr. Ulrich Reimann-Philipp,
Biologist and Cultivation Manager at GBLX. Dr. Reimann-Philip's
goal was to optimize the growth conditions within the GrowBLOX and
implement hardware and software updates.
About Growblox Sciences, Inc.
Growblox Sciences, Inc. (OTCQB:GBLX) is a biopharmaceutical
research and development company focused on creating safe,
standardized pharmaceutical-grade cannabis-based therapies that
target a variety of medical conditions. The Company is leading
pioneering technology and industry processes, with a "big"
data-driven clinical research and development loop ability to bring
relief to patients in communities across the country. Through
our GBS PR subsidiary, we are developing and globally distributing
our GrowBLOXTM suite of cultivation and growing chambers. To learn
more about Growblox Sciences, Inc., go to www.gbsciences.com.
Forward-Looking Statements: This press release
may contain statements relating to future results or events, which
are forward-looking statements. Words such as "expects", "intends",
"plans", "may", "could", "should", "anticipates", "likely",
"believes" and words of similar import may identify forward-looking
statements. These statements are not historical facts, but instead
represent only the Company's belief regarding future events, many
of which, by their nature, are inherently uncertain and outside of
the Company's control. It is possible that the Company's actual
results and financial condition may differ, possibly materially,
from the anticipated results and financial condition indicated in
these forward-looking statements. Further, information concerning
the Company and its business, including factors that potentially
could materially affect the Company's business and financial and
other results, are contained in the Company's filings with the
Securities and Exchange Commission, available at www.sec.gov. All
forward-looking statements included in this press release are made
only as of the date of this press release, and we do not undertake
any obligation to publicly update or correct any forward-looking
statements to reflect events or circumstances that subsequently
occur or of which we hereafter become aware.
Note: Although the Company's research and
development activities are not illegal, the production and sale of
cannabis products violate federal laws as presently
constituted.
GrowBLOX is a registered trademark of Growblox Sciences,
Inc.
CONTACT: Growblox Sciences, Inc., 6450 Cameron Street,
Suite 110A, Las Vegas, NV 89118 866.721.0297
Craig Ellins, CEO; Andrea Small Howard, Chief Science Officer.
craig@gbsciences.com
andrea@gbsciences.com
https://gbsciences.com
GB Sciences (PK) (USOTC:GBLX)
Historical Stock Chart
From Mar 2024 to Apr 2024
GB Sciences (PK) (USOTC:GBLX)
Historical Stock Chart
From Apr 2023 to Apr 2024